| Staphylococcus aureus infection |
1.83 |
1.04e-1 |
72/95 (75.79%) |
CFI;HLA-DOB;HLA-DQB1;...
|
| Complement and coagulation cascades |
1.73 |
1.30e-1 |
76/85 (89.41%) |
PLAT;SERPINA1;CFI;...
|
| Systemic lupus erythematosus |
1.72 |
1.14e-1 |
45/135 (33.33%) |
HLA-DOB;HLA-DQB1;C2;...
|
| Asthma |
1.70 |
1.06e-1 |
25/31 (80.65%) |
FCER1A;HLA-DOB;FCER1G;...
|
| Intestinal immune network for IgA production |
1.62 |
1.79e-1 |
38/48 (79.17%) |
HLA-DOB;HLA-DQB1;CD86;...
|
| RNA polymerase |
1.58 |
1.95e-1 |
23/31 (74.19%) |
POLR2L;POLR3B;POLR3G;...
|
| Fluid shear stress and atherosclerosis |
1.48 |
3.91e-1 |
123/139 (88.49%) |
PLAT;RAC2;CYBA;...
|
| Histidine metabolism |
1.46 |
3.80e-1 |
16/22 (72.73%) |
ALDH7A1;MAOA;ALDH2;...
|
| Arachidonic acid metabolism |
1.40 |
5.49e-1 |
48/61 (78.69%) |
ALOX5;PLA2G2A;GPX3;...
|
| Fc epsilon RI signaling pathway |
1.39 |
5.42e-1 |
57/68 (83.82%) |
ALOX5;RAC2;FCER1A;...
|
| Type II diabetes mellitus |
1.38 |
5.28e-1 |
42/46 (91.3%) |
SOCS1;PKM;MAPK10;...
|
| Linoleic acid metabolism |
1.37 |
5.42e-1 |
21/29 (72.41%) |
PLA2G2A;PLAAT3;PLA2G10;...
|
| Allograft rejection |
1.36 |
5.31e-1 |
32/38 (84.21%) |
HLA-DOB;HLA-DQB1;FAS;...
|
| Tryptophan metabolism |
1.35 |
5.33e-1 |
35/42 (83.33%) |
ALDH7A1;MAOA;KMO;...
|
| Apoptosis |
1.34 |
5.16e-1 |
126/168 (75%) |
CTSK;CTSH;CASP10;...
|
| alpha-Linolenic acid metabolism |
1.32 |
5.76e-1 |
17/25 (68%) |
PLA2G2A;FADS2;PLAAT3
|
| Ascorbate and aldarate metabolism |
1.32 |
5.51e-1 |
15/30 (50%) |
ALDH7A1;UGT2B28;ALDH2;...
|
| Viral myocarditis |
1.32 |
5.23e-1 |
53/60 (88.33%) |
RAC2;CAV1;HLA-DOB;...
|
| Ribosome |
1.31 |
4.99e-1 |
113/158 (71.52%) |
RPL36;RPS5;RPL13;...
|
| Sulfur metabolism |
1.29 |
5.60e-1 |
9/10 (90%) |
PAPSS1;TST;PAPSS2;...
|
| Retinol metabolism |
1.29 |
5.38e-1 |
41/68 (60.29%) |
ADH1B;UGT2B28;ALDH1A2;...
|
| Coronavirus disease |
1.27 |
5.65e-1 |
215/232 (92.67%) |
F13A1;OAS3;OAS1;...
|
| Glycosaminoglycan biosynthesis |
1.26 |
5.80e-1 |
40/58 (68.97%) |
HS3ST1;EXT1;EXTL2;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
1.26 |
5.82e-1 |
5/5 (100%) |
HK2;HK3;HKDC1
|
| Arginine and proline metabolism |
1.26 |
5.64e-1 |
39/50 (78%) |
ALDH7A1;MAOA;ALDH2;...
|
| Lysine degradation |
1.25 |
5.48e-1 |
51/63 (80.95%) |
ALDH7A1;SUV39H1;ALDH2;...
|
| Cytosolic DNA-sensing pathway |
1.25 |
5.36e-1 |
52/63 (82.54%) |
AIM2;POLR2L;POLR3B;...
|
| Influenza A |
1.25 |
5.24e-1 |
156/172 (90.7%) |
TNFSF10;HLA-DOB;OAS3;...
|
| Fatty acid biosynthesis |
1.24 |
5.52e-1 |
16/18 (88.89%) |
FASN;ACSL4;ACSL1;...
|
| Pentose and glucuronate interconversions |
1.23 |
5.47e-1 |
17/34 (50%) |
DCXR;UGT2B28;AKR1B1;...
|
| Oxidative phosphorylation |
-1.30 |
4.15e-1 |
93/133 (69.92%) |
COX7A2L;NDUFAB1;NDUFS2;...
|
| Huntington disease |
-1.31 |
4.11e-1 |
233/306 (76.14%) |
NRBF2;GRIA3;IFT57;...
|
| Alzheimer disease |
-1.31 |
4.23e-1 |
279/369 (75.61%) |
ULK1;EIF2S1;NDUFV1;...
|
| Human immunodeficiency virus 1 infection |
-1.32 |
4.20e-1 |
189/212 (89.15%) |
BAX;CD3G;PRKCA;...
|
| Human cytomegalovirus infection |
-1.34 |
4.16e-1 |
201/225 (89.33%) |
GSK3B;PTGER4;RHEB;...
|
| Glyoxylate and dicarboxylate metabolism |
-1.35 |
3.84e-1 |
23/30 (76.67%) |
HAO1;PCCB;ACO2;...
|
| Synthesis and degradation of ketone bodies |
-1.36 |
3.60e-1 |
9/10 (90%) |
BDH1;HMGCS2;ACAT2;...
|
| Lipid and atherosclerosis |
-1.37 |
3.66e-1 |
190/215 (88.37%) |
GSK3B;IL18;NOX1;...
|
| Spinocerebellar ataxia |
-1.37 |
3.80e-1 |
128/143 (89.51%) |
TBP;PSMA3;PSMD12;...
|
| Oxytocin signaling pathway |
-1.37 |
3.94e-1 |
128/154 (83.12%) |
PRKAB2;GNAI1;PLCB3;...
|
| Various types of N-glycan biosynthesis |
-1.37 |
4.03e-1 |
26/39 (66.67%) |
MGAT1;STT3A;B4GALT3;...
|
| Thyroid cancer |
-1.37 |
4.18e-1 |
36/37 (97.3%) |
CCDC6;TFG;BAX;...
|
| Pathways of neurodegeneration |
-1.40 |
4.22e-1 |
354/475 (74.53%) |
COX7A2L;MAPK13;FRAT2;...
|
| Glutamatergic synapse |
-1.40 |
4.10e-1 |
97/114 (85.09%) |
GRM3;GNAI1;PLCB3;...
|
| Inositol phosphate metabolism |
-1.41 |
4.16e-1 |
66/73 (90.41%) |
INPP5E;PIK3CA;MTMR6;...
|
| GABAergic synapse |
-1.46 |
3.33e-1 |
76/89 (85.39%) |
PRKCA;GABRA5;GABRR1;...
|
| Nitrogen metabolism |
-1.46 |
3.34e-1 |
16/17 (94.12%) |
CA12;GLUD2;GLUD1
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.48 |
3.20e-1 |
172/193 (89.12%) |
HLA-G;FOS;HIF1A;...
|
| NF-kappa B signaling pathway |
-1.48 |
3.41e-1 |
90/104 (86.54%) |
CD14;BCL2L1;CXCL3;...
|
| Thyroid hormone signaling pathway |
-1.50 |
3.36e-1 |
112/121 (92.56%) |
PLCE1;AKT3;PLCB3;...
|
| Arginine biosynthesis |
-1.52 |
2.93e-1 |
17/22 (77.27%) |
ASS1;GOT2;GLUD2;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.53 |
3.02e-1 |
79/89 (88.76%) |
CD3G;FOS;MAP2K3;...
|
| Pertussis |
-1.53 |
3.33e-1 |
64/76 (84.21%) |
IL1A;IL6;IRAK4;...
|
| Th17 cell differentiation |
-1.55 |
3.21e-1 |
95/107 (88.79%) |
CD3G;RUNX1;FOS;...
|
| Caffeine metabolism |
-1.59 |
2.73e-1 |
5/6 (83.33%) |
NAT2;CYP2A6;NAT1
|
| Alanine, aspartate and glutamate metabolism |
-1.60 |
3.01e-1 |
27/37 (72.97%) |
ASRGL1;NIT2;ASS1;...
|
| mTOR signaling pathway |
-1.62 |
3.21e-1 |
114/154 (74.03%) |
RPS6KA1;TELO2;MIOS;...
|
| Proteasome |
-1.64 |
3.94e-1 |
44/46 (95.65%) |
PSMF1;PSMA3;PSMD12;...
|
| Glycosphingolipid biosynthesis |
-1.76 |
2.01e-1 |
37/57 (64.91%) |
FUT9;B3GALNT1;B4GALNT1;...
|
| Primary immunodeficiency |
-1.77 |
3.25e-1 |
33/38 (86.84%) |
ADA;TAP2;CD8A;...
|
